Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma.

• DOI: 10.1200/jco.2024.42.3_suppl.674
• Publication Date: 2024-01-22T21:12:58Z
• Authors: Andrea Pretta; Riccardo Giampieri; Federico Nichetti; Pina Ziranu; Alessio Lupi; Giusy Moledda; Paola Andena; Cristiano Felicetti; Alessandra Pia D'...; Chiara Carlotta P...; Claudia Codipietro; Simone Rota; Daiana Rizzo; Giorgia Sanna; Eleonora Lai; Marco Puzzoni; Valeria Pusceddu; Rossana Berardi; Monica Niger; Mario Scartozzi
• Keywords: Clinical endpoint; Therapeutic effect

674 Background: The first-line treatment of metastatic pancreatic cancer involves different therapeutic regimens, among them, mFOLFIRINOX and gemcitabine-nabpaclitaxel. However, it remains to be clarified which sequence might correlate with better outcomes. aim our work was evaluate leads overall survival in this setting. Methods: We retrospectively collected data from 358 patients affected by stage IV ductal adenocarcinoma 3 Italian Institutions. Patients received or gemcitabine plus nabpaclitaxel as chemotherapy, followed a second-line non-cross-resistant chemotherapy (gemcitabine fluoropyrimidine-based combinations). Survival distribution assessed Kaplan-Meier curves. primary endpoint median survival. Statistical analysis performed MedCalc package. Results: age 66 (± 9), 195 (54,4%) were male 163 (45,6%) female. 292 (81,5%) start first line treatment, while (18,5%) therapy. No statistically significant differences terms mOS observed between the two gemcitabine-nabpaclitaxel groups: 16 versus 15 months, respectively, p = 0,2). found mPFS either: 7 8 0,3). Conclusions: results retrospective study showed no advantage sequences starting Further studies will necessary establish effectiveness new schemes introduced into clinical practice order define algorithm.